2024-04-18 13:46:03 ET
Addex Therapeutics Ltd (ADXN)
Q4 2023 Earnings Conference Call
April 18, 2024, 10:00 AM ET
Company Participants
Tim Dyer - Chief Executive Officer
Mikhail Kalinichev - Head, Translational Science
Conference Call Participants
Joanne Lee - Maxim Group
Raghuram Selvaraju - H.C. Wainwright & Co.
Michael Okunewitch - Maxim Group
Presentation
Operator
Good day and thank you for standing by. Welcome to the Addex Therapeutics Full Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After the speaker’s presentation, there will be the question-and-answer session. [Operator Instructions]
Please be advised that today’s conference has been recorded. I would now like to hand the conference over to our speaker today, Tim Dyer. Please go ahead.
Tim Dyer
Hello, everyone. I’d like to thank you all for attending our 2023 financial results conference call. I’m here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D program. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website.
I also draw your attention to our disclaimer. We will be making certain forward-looking statements that are based on the knowledge we have today.
I will start this conference call by giving a quick overview of the 2023 activities and recent achievements before reviewing our pipeline. I will then hand over to Mikhail, who will review in more detail some of the clinical and preclinical programs. I will then speak about the recent launch of Neurosterix before reviewing our 2023 full year financial results. Following that, we will open the call for Q&A....
Read the full article on Seeking Alpha
For further details see:
Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript